Home›Trial›NCT04540900
NCT04540900Phase 1ACTIVE NOT RECRUITING

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Study Summary

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Conditions
Skin RoughnessWrinkleFine LinesSkin Thickness
Interventions / Drugs
KB301Placebo
View on ClinicalTrials.gov ↗
Sponsor
KRYS
Krystal Biotech
Gene Therapy
F29/100
Study Details
Enrollment85 participants
Primary Completion—
Lead SponsorKrystal Biotech, Inc.
Data Retrieved2026-04-11 04:19:09.549381+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 85 participants
Sponsor Catalyst Profile

Krystal Biotech (KRYS) is the sponsoring company for this trial. BiotechSign currently grades this company F (29/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

KRYS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.